Immuneering (IMRX) Interest & Investment Income (2020 - 2026)
Immuneering's (IMRX) quarterly Interest & Investment Income came in at $1.4 million in Q1 2026, up 210.23% year-on-year from $438520.0 in Q1 2025, and down 26.9% quarter-over-quarter from $1.9 million in Q4 2025.
Immuneering (IMRX) Interest & Investment Income (2020 - 2026) Analysis & Trends
Immuneering's Interest & Investment Income history runs 7 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 210.23% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 77.88% increase from a year earlier, with the FY2025 full-year figure at $3.0 million, up 17.2% from the prior year.
- Interest & Investment Income eased to $1.4 million in Q1 2026 per IMRX's latest filing, from $1.9 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.9 million in Q4 2025 and bottomed at $132506.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $547072.0 (2024), against an average of $683209.8.
- Across the five-year window, Interest & Investment Income soared 4281.68% in 2022 and plunged 60.78% in 2025, its largest moves.
- Year by year, Interest & Investment Income stood at $516168.0 in 2022, then surged by 46.1% to $754144.0 in 2023, then plunged by 44.94% to $415240.0 in 2024, then soared by 348.19% to $1.9 million in 2025, then declined by 26.9% to $1.4 million in 2026.
- Per Business Quant, the three latest IMRX Interest & Investment Income figures stand at $1.4 million (Q1 2026), $1.9 million (Q4 2025), and $415831.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Immuneering | 282.24 Mn | 282.24 Mn | - | 1.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.36 Mn |
| Dec 31, 2025 | 1.86 Mn |
| Sep 30, 2025 | 415,831.00 |
| Jun 30, 2025 | 324,013.00 |
| Mar 31, 2025 | 438,520.00 |
| Dec 31, 2024 | 415,240.00 |
| Sep 30, 2024 | 547,072.00 |
| Jun 30, 2024 | 826,104.00 |
| Mar 31, 2024 | 804,884.00 |
| Dec 31, 2023 | 754,144.00 |
| Sep 30, 2023 | 855,532.00 |
| Jun 30, 2023 | 1.17 Mn |
| Mar 31, 2023 | 831,274.00 |
| Dec 31, 2022 | 516,168.00 |
| Sep 30, 2022 | 222,985.00 |
| Jun 30, 2022 | 142,799.00 |
| Mar 31, 2022 | 132,506.00 |
| Dec 31, 2021 | 142,885.00 |
| Sep 30, 2021 | 17,400.00 |
| Jun 30, 2021 | 3,259.00 |